Early detection plays a vital role in treating pancreatic cancer and increases the chance of surviving the lethal disease. Learn from cancer pathologist Michael Goggins, director of the Pancreatic Cancer Early Detection Laboratory, about new strategies — including identifying gene variants responsible for inherited susceptibility to pancreatic cancer — to reduce the risk of pancreatic cancer and to detect the disease.

Dr. Michael G. Goggins is a professor of pathology, medicine and oncology at the Johns Hopkins University School of Medicine. He serves as director of the Pancreatic Cancer Early Detection Laboratory and is an attending physician in medicine in the Division of Gastroenterology and Hepatology at The Johns Hopkins Hospital. He is the Sol Goldman Professor of Pancreatic Cancer Research.

Dr. Goggins’ research interests include developing tests to improve the early detection in pancreas cancer, evaluating outcomes of pancreatic surveillance and identifying gene variants responsible for inherited susceptibility to pancreatic cancer.

He obtained his medical degree in 1988 from Trinity College of the University of Dublin, Ireland. He completed a residency in internal medicine and a fellowship in Gastroenterology at St. James' Hospital in Dublin. He obtained his Membership of the Royal College of Physicians of Ireland in 1991 and his European Diploma in Gastroenterology in 1995. He joined the Johns Hopkins faculty in 1999.